, Volume 178, Issue 4, pp 514–523

Ziprasidone and haloperidol in the treatment of acute exacerbation of schizophrenia and schizoaffective disorder: comparison of intramuscular and oral formulations in a 6-week, randomized, blinded-assessment study

  • Shlomo Brook
  • Jeorg Walden
  • Isma Benattia
  • Cynthia O. Siu
  • Steven J. Romano
Original Investigation



Conventional intramuscular (IM) antipsychotics used in managing acute exacerbation of schizophrenia are associated with side effects such as acute dystonia.


To compare the efficacy and tolerability of sequential IM/oral ziprasidone with haloperidol in acute exacerbation of schizophrenia or schizoaffective disorder.


In a 6-week, multicenter, parallel-group, flexibly dosed study, patients were randomized to ziprasidone (IM up to 3 days, then oral 40–80 mg, b.i.d.) or haloperidol (IM up to 3 days, then oral 5–20 mg/day). Assessments were rater-blinded.


At the end of IM treatment, patients receiving ziprasidone (n=427) showed significantly improved Brief Psychiatric Rating Scale Total (BPRS total) scores compared with those receiving haloperidol (n=138) [least-squares (LS) mean change −6.14 for ziprasidone versus −4.13 for haloperidol, P<0.0018]. At endpoint, there were no significant between-group differences in BPRS total scores. There was a significantly greater improvement in BPRS negative subscale scores in ziprasidone-treated patients, both at the end of IM treatment (LS mean change −1.15 for ziprasidone and −0.28 for haloperidol, P<0.0001) and at study endpoint (LS mean change −2.94 for ziprasidone and −2.24 for haloperidol, P<0.0001). Haloperidol-treated patients exhibited significantly greater increases in Extrapyramidal Symptom Rating Scale at end of IM treatment and at endpoint (P<0.0001). They also had significantly higher ratings on the Barnes Akathisia Scale (P<0.0001) and the Movement Disorder Burden Score (P<0.005), as well as higher incidences of movement disorder-related adverse events.


Sequential IM and oral ziprasidone offers important efficacy and tolerability advantages over haloperidol in acute schizophrenia.


Acute schizophrenia Antipsychotics Haloperidol Schizophrenia Sequential intramuscular/oral Ziprasidone 


  1. Addington D, Pantelis C, Benattia I (2002) Ziprasidone vs. risperidone in schizophrenia: an 8-week, double-blind trial. Eur Neuropsychopharmacol 12(Suppl 3):S314. Abstract P.2.142CrossRefGoogle Scholar
  2. Arató M, O’Connor R, Bradbury JE, Meltzer H, ZEUS Study Group (2002) Ziprasidone in long-term treatment of negative symptoms and prevention of exacerbation of schizophrenia. Int Clin Psychopharmacol 17:207–215CrossRefGoogle Scholar
  3. Brook S, Lucey JV, Gunn KP, Ziprasidone IM Study Group (2000) Intramuscular ziprasidone compared with intramuscular haloperidol in the treatment of acute psychosis. J Clin Psychiatry 61:933–941Google Scholar
  4. Covi L, Lipman RS, McNair DM, Czerlinsky T (1979). Symptomatic volunteers in multicenter drug trials. Prog Neuro-Psychopharmacol 2:521–533Google Scholar
  5. Daniel DG, Zimbroff DL, Potkin SG, Reeves KR, Harrigan EP, Lakshminarayanan M, Ziprasidone Study Group (1999) Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Neuropsychopharmacology 20:491–505CrossRefGoogle Scholar
  6. Daniel DG, Potkin SG, Reeves KR, Swift RH, Harrigan EP (2001) Intramuscular (IM) ziprasidone 20 mg is effective in reducing acute agitation associated with psychosis: a double-blind, randomized trial. Psychopharmacol (Berl) 155:128–134CrossRefGoogle Scholar
  7. Foster S, Kessel J, Berman ME, Simpson GM (1997) Efficacy of lorazepam and haloperidol for rapid tranquilization in a psychiatric emergency room setting. Int Clin Psychopharmacol 12:175–179PubMedGoogle Scholar
  8. Glick ID, Fryburg D, O’Sullivan RL, Siu C, Simpson G (2001) Ziprasidone’s benefits vs. olanzapine regarding weight and insulin resistance. Eur Neuropsychopharmacol 11(Suppl 3):S273. Abstract P.2.070CrossRefGoogle Scholar
  9. Goff DC, Posever T, Herz L, Simmons J, Kletti N, Lapierre K, Wilner KD, Law CG, Ko GN (1998) An exploratory haloperidol-controlled dose-finding study of ziprasidone in hospitalized patients with schizophrenia or schizoaffective disorder. J Clin Psychopharmacol 18:296–304CrossRefGoogle Scholar
  10. Hirsch S, Kissling W, Bauml J, Power A, O’Connor R (2002) A 28-week comparison of ziprasidone and haloperidol in outpatients with stable schizophrenia. J Clin Psychiatry 63:516–523Google Scholar
  11. Keck P Jr, Buffenstein A, Ferguson J, Feighner J, Jaffe W, Harrigan EP, Morrissey MR (1998) Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 4-week placebo-controlled trial. Psychopharmacology 140:173–184CrossRefGoogle Scholar
  12. Keck PE, Reeves KR, Harrigan EP (2001) Ziprasidone in the short-term treatment of patients with schizoaffective disorder: results from two double-blind, placebo-controlled, multicenter studies. J Clin Psychopharmacol 21:27–35CrossRefGoogle Scholar
  13. Lesem MD, Zajecka JM, Swift RH, Reeves KR, Harrigan EP (2001) Intramuscular ziprasidone, 2 mg vs. 10 mg, in the short-term management of agitated psychotic patients. J Clin Psychiatry 62:12–18Google Scholar
  14. Simpson G, O’Sullivan RL, Siu C (2001) Ziprasidone vs. olanzapine in schizophrenia: results of a double-blind trial. Eur Neuropsychopharmacol 11(Suppl 3):S274. Abstract P.2.073CrossRefGoogle Scholar
  15. Simpson GM, Weiden P, Pigott T, Romano SJ, Siu C (2002) Ziprasidone vs. olanzapine in schizophrenia: 6-month continuation study. Eur Neuropsychopharmacol 12(Suppl 3):S310. Abstract P.2.134CrossRefGoogle Scholar
  16. Swift RH, Harrigan EP, Cappelleri JC, Kramer D, Chandler LP (2002) Validation of the behavioural activity rating scale (BARS): a novel measure of activity in agitated patients. J Psychiatr Res 36:87–95CrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2005

Authors and Affiliations

  • Shlomo Brook
    • 1
  • Jeorg Walden
    • 2
  • Isma Benattia
    • 3
  • Cynthia O. Siu
    • 3
  • Steven J. Romano
    • 3
  1. 1.Department of PsychiatrySterkfontein HospitalKrugersdorpSouth Africa
  2. 2.Universitätsklinik für Psychiatrie und PsychosomatikFreiburgGermany
  3. 3.Pfizer IncNew YorkUSA

Personalised recommendations